Intuitive Surgical Announces Second Quarter Results

July 27, 2000 at 4:11 PM EDT

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--July 27, 2000--Intuitive Surgical, Inc. (Nasdaq:ISRG), today reported sales of $5.1 million in the second quarter of 2000, up 41% from $3.6 million in sales reported in the second quarter of 1999. Sales increased by $2.2 million, or 75%, from the first quarter of 2000. This growth in revenue was driven by the sale and installation of six da Vinci(TM) Surgical Systems in the second quarter of 2000, compared with four da Vinci(TM) Surgical Systems in the second quarter of 1999 and three da Vinci(TM) Surgical Systems in the first quarter of 2000.

Gross margin for the second quarter of 2000 was 32%, compared with 11% for the second quarter of 1999 and 14% for the first quarter of 2000. This improvement resulted from higher sales and increased manufacturing efficiencies.

Net loss for the second quarter of 2000 was $4.5 million, compared to a net loss of $3.3 million for the second quarter of 1999 and $5.0 million for the first quarter of 2000. Basic and diluted net loss per share was $0.23 for the second quarter of 2000, compared to a net loss per share of $0.70 for the second quarter of 1999. The weighted average shares used to compute net loss per share was approximately 19.8 million shares for the second quarter of 2000 and approximately 4.6 million shares for the second quarter of 1999. Common shares outstanding at the end of the second quarter 2000 was approximately 34.9 million shares.

The company will also announce these results at a conference call today at 1:30pm PDT.

Commenting on the announcement, Lonnie Smith, president and CEO of Intuitive Surgical, said: "We are very pleased with our second quarter results and the growth in sales of our da Vinci(TM) Surgical Systems. Up to now, most of our clinical successes have been focused in Europe. With the recent clearance we received from the FDA, we are now positioned to expand the use of our products in the United States."

On July 11, 2000 the Company received clearance from the FDA to market the da Vinci(TM) Surgical System in the United States for use in laparoscopic surgical procedures. Intuitive now has the only FDA-cleared, complete robotic system available for surgery in the United States.

In June 2000, the Company sold 5.0 million shares of common stock at a price of $9.00 per share in connection with its initial public offering. In July 2000, the Company sold an additional 750,000 shares of common stock at a price of $9.00 per share upon the exercise of the underwriters' over-allotment option.

About the da Vinci(TM) Surgical System:

The da Vinci(TM) Surgical System consists of a surgeon's viewing and control console having an integrated, high-performance 3-D vision system, a patient-side cart consisting of three robotic arms that position and precisely maneuver endoscopic instruments and an endoscope, and a variety of articulating EndoWrist(TM) Instruments. By integrating computer-enhanced, robotic technology with surgeons' technical skills, Intuitive believes that its System enables surgeons to perform better surgery in a manner never before experienced. The da Vinci(TM) Surgical System seamlessly and directly translates the surgeon's natural hand, wrist and finger movements on instrument controls at the surgeon's console outside the patient's body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions, or ports.

The statements contained in this release may be deemed to contain "forward-looking statements." Such statements are indicated by words or phrases such as "anticipate," "estimate," "projects," "believes," "intends," "expects" and similar words and phrases. Actual results may differ materially from those expressed or implied in any forward-looking statement as a result of certain risks and uncertainties, including, without limitation, competition and market acceptance of the Company's products, ability to obtain regulatory approvals and third-party reimbursement, ability to raise additional capital and other risks and uncertainties detailed in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

Note to Editors: Intuitive(TM), da Vinci(TM), and EndoWrist(TM) are trademarks of Intuitive Surgical, Inc. -0-

                   INTUITIVE SURGICAL, INCORPORATED
                 CONSOLIDATED STATEMENTS OF OPERATIONS
                 (IN THOUSANDS, EXCEPT PER-SHARE DATA)

                                              Three months ended
                                           June 30,       June 30,
                                             2000           1999
                                          (unaudited)    (unaudited)

Sales                                         5,127          3,635
Cost of sales                                 3,503          3,243
  Gross profit                                1,624            392

Operating costs and expenses:
  Research and development                    2,822          1,807
  Selling, general and administrative         3,976          2,228
    Total operating costs and expenses        6,798          4,035

Loss from operations                         (5,174)        (3,643)

Interest income                                 802            461
Interest expense                               (118)           (93)

Net loss                                   $ (4,490)      $ (3,275)

Weighted average shares outstanding
 used to compute net loss per share          19,808          4,649

Loss per share --
 basic and diluted                         $  (0.23)      $  (0.70)



                   INTUITIVE SURGICAL, INCORPORATED
                      CONSOLIDATED BALANCE SHEETS
                            (IN THOUSANDS)

                                           June 30,     December 31,
                                             2000           1999
                                          (unaudited)
Assets
Current assets:
  Cash, cash equivalents and
   short-term investments                    87,340         26,260
  Accounts receivable                         5,285          2,044
  Inventories                                 4,796          2,861
  Prepaid expenses                            1,014            581
    Total current assets                     98,435         31,746

Property and equipment, net                   3,672          2,709
Other assets                                  4,465             --

Total assets                                106,572         34,455

Liabilities and stockholders' equity
Current Liabilities:
  Accounts payable                            4,825          2,722
  Accrued compensation and
   employee benefits                          1,336          1,325
  Warranty provision                          1,115            812
  Accrued liabilities                         1,485          1,116
  Deferred revenue                            2,744          2,130
  Current portion of notes payable            1,746          1,618
    Total current liabilities                13,251          9,723

Notes payable                                 2,038          2,521

Stockholders' equity
  Preferred stock                                --             19
  Common stock                                   35              7
  Additional paid-in capital                180,171         98,508
  Deferred compensation                      (3,964)          (943)
  Accumulated deficit                       (84,669)       (75,147)
  Accumulated other comprehensive income       (290)          (233)
    Total stockholders' equity               91,283         22,211

Total liabilities and
 stockholders' equity                       106,572         34,455



   CONTACT: Intuitive Surgical, Inc.
            Sheila Shah, 650/237-7073